Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

YM reports nimotuzumab data in gastric cancer

January 21, 2011 12:42 AM UTC

YM BioSciences Inc. (TSX:YM; NYSE-A:YMI) reported preliminary data from a Phase II trial of nimotuzumab in patients with advanced or recurrent gastric cancer who are refractory to a 5-fluorouracil (5-FU)-containing regimen. The mAb against EGFR plus IV irinotecan led to worse median progression-free survival (PFS), the primary endpoint, vs. irinotecan alone at a median follow-up of 197 days (73 vs. 85 days). Median overall survival for nimotuzumab plus irinotecan was 293 days vs. 227 days for irinotecan alone. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article